Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 3
2 (100.0%)Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03
Phase 3
Completed
- Conditions
- Breast NeoplasmsEarly-stage Breast CancerBreast CancerHER2-positive Breast CancerStage II Breast CancerStage IIIA Breast Cancer
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Tanvex BioPharma USA, Inc.
- Target Recruit Count
- 338
- Registration Number
- NCT04109391
- Locations
- 🇧🇾
Tanvex Investigational Site 1003E, Gomel, Belarus
🇧🇾Tanvex Investigational Site 1006E, Grodno, Belarus
🇧🇾Tanvex Investigational Site 1008E, Lesnoy, Belarus
Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer
Phase 3
Completed
- Conditions
- Stage II Breast CancerStage IIIA Breast CancerBreast CancerBreast NeoplasmsHER2-positive Breast Cancer
- Interventions
- Biological: Herceptin®Biological: TX05 (trastuzumab)
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Tanvex BioPharma USA, Inc.
- Target Recruit Count
- 809
- Registration Number
- NCT03556358
- Locations
- 🇧🇾
Tanvex Investigational Site 1008, Lesnoy, Minsk Region, Belarus
🇧🇾Tanvex Investigational Site 1007, Babruysk, Mogilev Region, Belarus
🇧🇾Tanvex Investigational Site 1003, Gomel, Belarus
News
No news found